Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:DMRA NASDAQ:PTGX NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.62-0.5%$38.98$11.55▼$40.26$5.91B1.111.08 million shs1.70 million shsDMRADamora Therapeutics, Inc. Common Stock$21.01-5.8%$24.95$2.45▼$38.33$1.29B1.46322,141 shs523,534 shsPTGXProtagonist Therapeutics$97.38-5.3%$101.33$49.38▼$107.84$6.26B1.85501,511 shs887,396 shsRYTMRhythm Pharmaceuticals$86.40-1.4%$87.45$60.70▼$122.20$5.92B1.91599,926 shs446,275 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-0.45%-0.35%+0.05%+52.68%+216.20%DMRADamora Therapeutics, Inc. Common Stock-5.83%-15.55%-14.90%-27.33%+536.67%PTGXProtagonist Therapeutics-5.26%-2.19%-6.34%+5.74%+88.98%RYTMRhythm Pharmaceuticals-1.38%-2.17%-10.57%-7.61%+34.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$39.62-0.5%$38.98$11.55▼$40.26$5.91B1.111.08 million shs1.70 million shsDMRADamora Therapeutics, Inc. Common Stock$21.01-5.8%$24.95$2.45▼$38.33$1.29B1.46322,141 shs523,534 shsPTGXProtagonist Therapeutics$97.38-5.3%$101.33$49.38▼$107.84$6.26B1.85501,511 shs887,396 shsRYTMRhythm Pharmaceuticals$86.40-1.4%$87.45$60.70▼$122.20$5.92B1.91599,926 shs446,275 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals-0.45%-0.35%+0.05%+52.68%+216.20%DMRADamora Therapeutics, Inc. Common Stock-5.83%-15.55%-14.90%-27.33%+536.67%PTGXProtagonist Therapeutics-5.26%-2.19%-6.34%+5.74%+88.98%RYTMRhythm Pharmaceuticals-1.38%-2.17%-10.57%-7.61%+34.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 2.21Hold$41.334.32% UpsideDMRADamora Therapeutics, Inc. Common Stock 2.89Moderate Buy$42.0099.90% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.2118.31% UpsideRYTMRhythm Pharmaceuticals 2.83Moderate Buy$131.8152.56% UpsideCurrent Analyst Ratings BreakdownLatest DMRA, PTGX, RYTM, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026RYTMRhythm Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/28/2026DMRADamora Therapeutics, Inc. Common Stock WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$135.005/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/7/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $143.005/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.005/6/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$136.00 ➝ $137.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$15M394.17N/AN/A$3.92 per share10.11DMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A($110.11) per shareN/APTGXProtagonist Therapeutics$46.02M136.08N/AN/A$9.83 per share9.91RYTMRhythm Pharmaceuticals$189.76M31.20N/AN/A$2.08 per share41.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)DMRADamora Therapeutics, Inc. Common Stock-$209.84M-$5.58N/AN/AN/AN/A-428.30%-114.62%8/5/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)Latest DMRA, PTGX, RYTM, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026DMRADamora Therapeutics, Inc. Common Stock-$0.3878-$0.62-$0.2322-$0.62N/AN/A5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million3/31/2026Q4 2025CNTACentessa Pharmaceuticals-$0.38-$0.48-$0.10-$0.48$0.77 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ADMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.239.539.53DMRADamora Therapeutics, Inc. Common StockN/A22.4922.48PTGXProtagonist TherapeuticsN/A17.7617.76RYTMRhythm PharmaceuticalsN/A4.173.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%DMRADamora Therapeutics, Inc. Common Stock14.20%PTGXProtagonist Therapeutics98.63%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals4.09%DMRADamora Therapeutics, Inc. Common Stock0.40%PTGXProtagonist Therapeutics5.19%RYTMRhythm Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200149.23 million143.13 millionOptionableDMRADamora Therapeutics, Inc. Common Stock4061.55 million61.31 millionNo DataPTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableDMRA, PTGX, RYTM, and CNTA HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial EngineJune 3 at 8:40 AM | seekingalpha.comZweig DiMenna Associates LLC Buys New Shares in Rhythm Pharmaceuticals, Inc. $RYTMMay 30, 2026 | marketbeat.comRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026May 29, 2026 | globenewswire.comRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical GeneticsMay 28, 2026 | globenewswire.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Moderate Buy" from AnalystsMay 28, 2026 | americanbankingnews.comRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesMay 26, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (CRDF)May 22, 2026 | theglobeandmail.comRhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comHC Wainwright Issues Pessimistic Outlook for RYTM EarningsMay 13, 2026 | marketbeat.comComerica Bank Cuts Stake in Rhythm Pharmaceuticals, Inc. $RYTMMay 13, 2026 | marketbeat.comRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyMay 12, 2026 | markets.businessinsider.comRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyMay 12, 2026 | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Wall Street Zen to "Hold" RatingMay 9, 2026 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 8, 2026 | finance.yahoo.comRhythm Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare ConferenceMay 6, 2026 | globenewswire.comRhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth PotentialMay 5, 2026 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2026 | zacks.comRhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 5, 2026 | globenewswire.comHow The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE ExpansionMay 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMRA, PTGX, RYTM, and CNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$39.62 -0.18 (-0.45%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$39.62 0.00 (0.00%) As of 06/5/2026 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA$21.01 -1.30 (-5.83%) As of 06/5/2026 04:00 PM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Protagonist Therapeutics NASDAQ:PTGX$97.38 -5.41 (-5.26%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$98.71 +1.33 (+1.36%) As of 06/5/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Rhythm Pharmaceuticals NASDAQ:RYTM$86.40 -1.21 (-1.38%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$86.40 +0.00 (+0.01%) As of 06/5/2026 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
